Effect of Hyperuricaemia on Chronic Renal Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT03425708

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03425708
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03425708. Randomized; single masking; primary purpose treatment. Start 2017-01-01 (actual); primary completion 2018-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Hyperuricaemia on Chronic Renal Disease
Condition
Hyperuricemia
Condition
Chronic Renal Disease
Intervention (Drug)
20mg Febuxostat
Intervention (Drug)
40mg Febuxostat
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University (class: other)
Collaborator
The First People's Hospital of Xuzhou (class: other)

Record details

Record id
cardio:ct-nct03425708
Content hash
fc73c4bbd3e12f7b4110a312a95922f76f59007ed0a37bd9b8d80d6c6b4fff44